Stein-Erik Gullaksen
Overview
Explore the profile of Stein-Erik Gullaksen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ha T, Andresen V, Erikstein B, Popa M, Gullaksen S, Reikvam H, et al.
Br J Haematol
. 2024 Nov;
206(1):109-119.
PMID: 39582120
Resazurin, a phenoxazine used in cell viability assays, acts in vitro as an anti-leukaemic compound through the production of cellular reactive oxygen species (ROS) resulting in mitochondrial dysfunction and cell...
2.
Sefland O, Gullaksen S, Omsland M, Reikvam H, Galteland E, Tran H, et al.
Cytometry B Clin Cytom
. 2024 Jul;
106(6):485-496.
PMID: 39078053
Measurable residual disease (MRD) is detected in approximately a quarter of AML chemotherapy responders, serving as a predictor for relapse and shorter survival. Immunological control of residual disease is suggested...
3.
Kleftogiannis D, Gavasso S, Tislevoll B, van der Meer N, Motzfeldt I, Hellesoy M, et al.
iScience
. 2024 Jul;
27(7):110261.
PMID: 39021803
Mass cytometry by time-of-flight (CyTOF) is an emerging technology allowing for in-depth characterization of cellular heterogeneity in cancer and other diseases. Unfortunately, high-dimensional analyses of CyTOF data remain quite demanding....
4.
Vestrheim Thomsen L, Kleinmanns K, Anandan S, Gullaksen S, Abdelaal T, Iversen G, et al.
Cancers (Basel)
. 2023 Oct;
15(20).
PMID: 37894472
The prognosis of high-grade serous ovarian carcinoma (HGSOC) is poor, and treatment selection is challenging. A heterogeneous tumor microenvironment (TME) characterizes HGSOC and influences tumor growth, progression, and therapy response....
5.
Geelen I, Gullaksen S, Ilander M, Olssen-Stromberg U, Mustjoki S, Richter J, et al.
Ann Hematol
. 2023 Apr;
102(6):1395-1408.
PMID: 37119314
In order to improve molecular response for a discontinuation attempt in chronic myeloid leukemia (CML) patients in chronic phase, who had not achieved at least a molecular response <0.01% BCR-ABL1...
6.
Rim S, Sakkestad S, Zhou F, Gullaksen S, Skavland J, Chauhan S, et al.
Eur J Immunol
. 2023 Apr;
53(8):e2250254.
PMID: 37102399
Enterotoxigenic Escherichia coli (ETEC) is an important cause of children's and travelers' diarrhea, with no licensed vaccine. This study aimed to explore the role of cellular immunity in protection against...
7.
Tislevoll B, Hellesoy M, Fagerholt O, Gullaksen S, Srivastava A, Birkeland E, et al.
Nat Commun
. 2023 Mar;
14(1):1767.
PMID: 36997540
No abstract available.
8.
Tislevoll B, Hellesoy M, Fagerholt O, Gullaksen S, Srivastava A, Birkeland E, et al.
Nat Commun
. 2023 Jan;
14(1):115.
PMID: 36611026
Aberrant pro-survival signaling is a hallmark of cancer cells, but the response to chemotherapy is poorly understood. In this study, we investigate the initial signaling response to standard induction chemotherapy...
9.
Kleinmanns K, Gullaksen S, Bredholt G, Davidson B, Torkildsen C, Grindheim S, et al.
Cancers (Basel)
. 2022 Jul;
14(13).
PMID: 35804867
High-grade serous ovarian cancer (HGSOC) has poor prognosis and new treatment modalities are needed. Immunotherapy, with checkpoint inhibitors, have demonstrated limited impact. To evaluate the suitability for immunotherapeutics, contextualized preclinical...
10.
Anandan S, Thomsen L, Gullaksen S, Abdelaal T, Kleinmanns K, Skavland J, et al.
Cancers (Basel)
. 2021 Mar;
13(4).
PMID: 33670410
Improved molecular dissection of the tumor microenvironment (TME) holds promise for treating high-grade serous ovarian cancer (HGSOC), a gynecological malignancy with high mortality. Reliable disease-related biomarkers are scarce, but single-cell...